Create Account | Sign In: Author or Forum

Search Symptoms

Category: Cardiology | Pharmacy | Journal

Back to Journal Articles

Similar Outcomes for Bivalirudin, Heparin in STEMI With PCI

Last Updated: May 19, 2017.

Similar outcomes are seen for use of bivalirudin and heparin as anticoagulant agents in patients with ST-segment elevation myocardial infarction treated with radial primary percutaneous coronary intervention, according to a study published online May 17 in JACC: Cardiovascular Interventions.

FRIDAY, May 19, 2017 (HealthDay News) -- Similar outcomes are seen for use of bivalirudin and heparin as anticoagulant agents in patients with ST-segment elevation myocardial infarction (STEMI) treated with radial primary percutaneous coronary intervention (PCI), according to a study published online May 17 in JACC: Cardiovascular Interventions.

Ion S. Jovin, M.D., Sc.D., from Virginia Commonwealth University in Richmond, and colleagues compared outcomes for patients with STEMI who underwent primary PCI via radial access and received bivalirudin or heparin as anticoagulation agents (29,660 and 37,708 patients, respectively).

The researchers observed no significant difference in the rate of the composite end point of death, myocardial infarction, or stroke in the unadjusted comparison (4.6 versus 4.7 percent; P = 0.47). The rate of acute stent thrombosis was significantly higher with bivalirudin versus heparin (1.00 versus 0.6 percent; P < 0.001). The odds ratio for the composite end point of death, myocardial infarction, or stroke was 0.95 (95 percent confidence interval, 0.87 to 1.05; P = 0.152) for bivalirudin versus heparin, after adjustment for multiple variables, including for a propensity score; the odds ratio for acute stent thrombosis was 2.11 (95 percent confidence interval, 1.73 to 2.57; P < 0.001). There was no significant difference noted in major bleeding rates.

"In patients undergoing primary PCI via transradial access anticoagulated with bivalirudin or heparin, there was no difference in the composite end point of death, myocardial infarction, or stroke," the authors write.

Two authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)


Previous: Anthropometric Measures of Body Fat ID Kidney Function Decline Next: Skin Needling + PRP Deemed More Effective Than Either Alone

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: